Acrivon Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 6 insiders sold shares within a monthSince Aug 18, 2026+4
Trials
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
11 sales (11 not pre-planned) · 0 purchases
- Miller MaryChief Legal Officer · Oct 22, 2026Sold 513 sharesabout $944 · not pre-planned
- Miller MaryChief Legal Officer · Oct 5, 2026Sold 294 sharesabout $585 · not pre-planned
- Blume-Jensen PeterPresident and CEO · Aug 25, 2026Sold 14,036 sharesabout $31 thousand · not pre-planned
- Peterson KatharineChief Accounting Officer · Aug 18, 2026Sold 101 sharesabout $203 · not pre-planned
- Miller MaryChief Legal Officer · Aug 18, 2026Sold 185 sharesabout $372 · not pre-planned
- Gamelin ErickChief Development Officer · Aug 18, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.